Atrium Therapeutics, Inc. Common Stock RNA · USD

Its shares trade under the ticker RNA. It has been listed since 28 June 2013. In the fiscal year to 31 December 2025, it reported revenue of $18.6m and a net loss of $76.7m. At that date it held total assets of $278.4m and shareholders' equity of $207.3m.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Troy WilsonIndependent Chairman of the Board$446,897
• Ms. Sarah BoycePresident, Chief Executive Officer, Director, since 2019$14.2m
• Mr. Michael MacleanChief Financial Officer$4.9m
• Ms. Teresa MccarthyChief Human Resources Officer$4.6m
• Mr. Charles CalderaroChief Technical Officer
• Dr. W. Michael FlanaganChief Scientific Officer$4.8m
• Dr. Arthur LevinDistinguished Scientist and Strategic Leader, Director, since 2014$3.0m
• Ms. Kathleen GallagherChief Program Officer
• Dr. Steven HughesChief Medical Officer
• Mr. Eric MosbrookerChief Commercial Officer, since 2021$235,311
• Mr. John MoriartyChief Legal Officer, Corporate Secretary$9.7m
• Mr. Carsten BoessIndependent Director$429,989

Overall

15

Environment

4

Social

22

Governance

17

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.